Clinical Features and Outcomes of Neuropsychiatric Systemic Lupus Erythematosus in China

Table 2

Comparison of clinical characteristics of the NPSLE and non-NPSLE groups.

	NPSLE group () (%)	Non-NPSLE group () (%)	value
Female	180 (92.8)	202 (91.8)	0.714
Age (years),			0.397
SLE duration (years),			0.535
Malar rash	136 (70.1)	79 (35.9)	<0.001
Oral ulcer	39 (20.1)	17 (7.7)	<0.001
Alopecia	75 (38.7)	52 (23.6)	0.001
Arthritis	60 (30.9)	41 (18.6)	0.004
Vasculitis	12 (6.2)	20 (9.1)	0.269
Serositis	84 (43.3)	21 (9.5)	<0.001
Renal involvement	103 (53.1)	82 (37.3)	0.001
Fever	79 (40.7)	35 (15.9)	<0.001
Leukopenia	97 (50.0)	40 (18.2)	<0.001
Thrombocytopenia	84 (43.3)	31 (14.1)	<0.001
ESR (mm/h)			<0.001
CRP (mg/L)			<0.001
Hypocomplementemia	153 (78.9)	138 (62.7)	<0.001
Anti-dsDNA positive	97 (50.0)	116 (52.7)	0.580
SLEDAI			<0.001
SLEDAI-removed NP scores			<0.001
Immunologic disorder at enrollment
Anti-Sm positive	69 (35.6)	114 (51.8)	0.001
Anti-RNP positive	101 (52.1)	121 (55.0)	0.489
Anti-SSA positive	126 (64.9)	151 (68.6)	0.436
Anti-SSB positive	34 (17.5)	72 (32.7)	0.001
Anti-ribosomal P protein positive	81 (41.8)	47 (21.4)	<0.001
Anticardiolipin positive	31 (16.6)	19 (11.7)	0.189
Lupus anticoagulant positive	38 (22.2)	44 (24.9)	0.562
Anti-β2 glycoprotein 1 positive	26 (14.3)	18 (9.6)	0.167

NPSLE: neuropsychiatric systemic lupus erythematosus; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; dsDNA: double-stranded deoxyribonucleic acid; SLEDAI: systemic lupus erythematosus disease activity index; NP: neuropsychiatric; RNP: ribonucleoprotein; Sm: Smith; SSA: Sjogren’s syndrome antigen A; SSB: Sjogren’s syndrome antigen B. Significant values are shown in bold typeface.